Best practices for the management of local-regional recurrent chordoma: a position paper by the chordoma global consensus group


To cite this version:


HAL Id: hal-02639001
https://hal.univ-lille.fr/hal-02639001
Submitted on 18 Nov 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License
Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group


1 Departments of Cancer Medicine; 2 Surgery, Fondazione IRCCS Istituto Nazionale Tumori, Milan; 3CNAO National Center for Oncological Hadrontherapy, Pavia; 4 Department of Radiotherapy, IEO European Institute of Oncology, Milan, Italy; 5 Department of Orthopaedic Surgery, Saitama Medical Center, Jichi Medical University, Saitama, Japan; 6 Department of Radiotherapy, Institut Curie, Paris; 7 Institut Curie—Centre de Protontherapie d’Orsay (CPPO), Orsay, France; 8 Department of Radiation Oncology, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universitat Dresden, Dresden, Germany; 9 Cancer Medicine, Department, Centre Leon Bérard, Lyon; 10 Department of Radiotherapy, Gustave Roussy, Villejuif Cedex, France; 11 Department of Degenerative and Oncological Spine Surgery, Rizzoli Institute Bologna, Bologna; 12 Department of Epidemiology, IRCCS Azienda Ospedaliero Universitaria San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, Genova; 13 University Clinic of Orthopedics and Traumatology AO Pisa, Pisa; 14 Palliative Care Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan; 15 Orthopedic Department, Rizzoli Institute Bologna, Bologna, Italy; 16 Department of Radiation Oncology, University of Heidelberg, Heidelberg, Germany; 17 Department of Radiation Oncology, Francis H. Burr Proton Therapy Center, Massachusetts General Hospital, Boston, USA; 18 Midlands Abdominal and Retropelvisonal Sarcoma Unit (MARSU), Queen Elizabeth Hospital, Birmingham; 19 Department of Oncology, University College London Hospitals (UCLH), London, UK; 20 Department of Orthopaedic Surgery, Leiden University Medical Centre, Leiden, The Netherlands; 21 Institute of Neurosurgery, University of Brescia, Brescia, Italy; 22 University College London Cancer Institute, London; 23 Histopathology Department, Royal National Orthopaedic Hospital NHS Trust, Stanmore, UK; 24 Department of Neurosurgery, Paris Diderot University, Paris, France; 25 Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, USA; 26 Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands; 27 Department of Neurosurgery, Brown University School of Medicine, Providence, USA; 28 Department of Radiotherapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands; 29 Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, USA; 30 Department of Cancer Medicine, Hospital Universitario Vigen del Risco, Seville, Spain; 31 Sarcoma Unit, Interdisciplinary Tumor Center, Mannheim University Medical Center, University of Heidelberg, Mannheim, Germany; 32 Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, USA; 33 National Institute of Radiological Sciences, Research Center Hospital for Charged Particle Therapy, Chiba, Japan; 34 Department of Orthopaedics, Royal Orthopaedic Hospital Birmingham, Birmingham; 35 Sarcoma Unit, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK; 36 Musculoskeletal Oncology and Rehabilitation Medicine, National Cancer Center, Tokyo, Japan; 37 Radiotherapy Department, University of Piemonte Orientale, Novara, Italy; 38 Department of Orthopaedics and Orthopaedic Surgery, University Medical Graz, Graz, Austria; 39 Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; 40 Department of Neurosurgery, IRCCS Istituto delle Scienze Neurologiche, Bologna; 41 Department of Radiology, Fondazione IRCCS Istituto Nazionale Tumori, Milan; 42 Department of Otorhinolaryngology—Head and Neck Surgery, University of Brescia, Brescia, Italy; 43 Department of Tumor Orthopaedic Surgery, The Norwegian Radium Hospital, Oslo, Norway; 44 Department of Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, USA; 45 Cancer Medicine Department, Oscar Lambret Cancer Centre, Lille, France; 46 Laboratory of Oncologic Research, Istituto Ortopedico Rizzoli, Bologna, Italy; 47 Laboratory of Molecular Pathology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; 48 Department of Neurosurgery, NYU Langone Medical Center, New York; 49 Center for Bone and Soft Tissue Sarcoma, Brigham and Women’s Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA; 50 Particle Therapy Department, West German Proton Therapy Centre Essen, University Hospital Essen, Essen, Germany; 51 Oncology Unit, IRCCS—Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; 52 Department of Orthopaedic Oncology, HELIOS Klinikum Berlin-Buch, Berlin, Germany; 53 Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA; 54 Paul Scherrer Institut PSI, Villigen, Switzerland; 55 Department of Radiology, Istituto Ortopedico Rizzoli, Bologna, Italy; 56 National Center for Spinal Disorders, Budapest, Hungary; 57 Department of Neurosurgery, Leiden University Medical Centre, Leiden, The Netherlands; 58 Chordoma Foundation, Durham, USA

© The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. This is an Open Access article under the CC-BY-NC License.
Chordomas are rare, malignant bone tumors of the skull-base and axial skeleton. Until recently, there was no consensus among experts regarding appropriate clinical management of chordoma, resulting in inconsistent care and suboptimal outcomes for many patients. To address this shortcoming, the European Society of Medical Oncology (ESMO) and the Chordoma Foundation, the global chordoma patient advocacy group, convened a multi-disciplinary group of chordoma specialists to define by consensus evidence-based best practices for the optimal approach to chordoma. In January 2015, the first recommendations of this group were published, covering the management of primary and metastatic chordomas. Additional evidence and further discussion were needed to develop recommendations about the management of local-regional failures. Thus, ESMO and CF convened a second consensus group meeting in November 2015 to address the treatment of locally relapsed chordoma. This meeting involved over 60 specialists from Europe, the United States and Japan with expertise in treatment of patients with chordoma. The consensus achieved during that meeting is the subject of the present publication and complements the recommendations of the first position paper.

Key words: chordoma, sarcoma, relapse, radiotherapy, surgery, chemotherapy

Introduction

Chordomas are rare, malignant bone tumors of the skull-base and axial skeleton [1]. Loco-regional recurrence is a common event following initial treatment of chordoma patients, and represents a major clinical challenge, which these recommendations seek to address. Loco-regional recurrence is defined as tumor relapse or progression after surgery and/or RT of the primary tumor at the same site and/or contiguous spreading of tumor from the primary site to adjacent areas. This includes progression of treated primary lesions, lesions recurring usually at, or near surgical margins, lesions that develop as a result of iatrogenic seeding along a biopsy or surgical tract, as well as skip metastases in the immediate vicinity of the tumor. In most cases, spread of the tumor is mediated by direct physical contact rather than dissemination via lymphatic, circulatory or subarachnoid routes. As such, cases with lymph node involvement are considered to have metastatic disease and are thus not addressed in these recommendations.

Published case series reporting post-surgical outcomes for chordoma indicate that loco-regional recurrence affects >50% of patients treated with macroscopic complete resection with or without RT (Tables 1–3). Notably, a high proportion of recurrences occur late (after 5 and 10 years), requiring long-term follow-up [2, 3]. Limited data are available about long-term recurrence-free survival (RFS), but all available long-term survival projections do not plateau, even after optimal local therapy. In particular, RFS or local control (LC) of skull-base chordomas at 5 and 10 years is 47–76% and 42–71% [3, 4], respectively, while 5- and 10-year estimated RFS for mobile spine chordomas is 58% and 32% [5]. Similarly, the 5-, 10- and 15-year local relapse (LR) incidence is reported to be 30%, 46% and 57%, respectively, in a recently published series of primary and completely resected sacral chordomas [6]. In this study, a plateau in RFS was not observed even at 15 years.

Major determinants of local control in primary chordomas at all sites include tumor size, extent of resection, quality of surgery, quality of RT (e.g. dose, volume, timing and dose inhomogeneity) and patient age [2, 7–9]. The experience of the treatment center may also play a role in the likelihood of recurrence.

Patients whose tumors recur/progress locally are challenging to control in the long-term and only a minority can be cured. Hence, every effort is needed to maximize the chances for long-term control of tumor with optimal management of the patient at the time of initial treatment. Nevertheless, with optimal treatment, long-term disease control and good quality of life (QOL) may still be possible for some patients. Thus, defining evidence-based best practice to manage this disease state is of utmost importance in order to improve patient outcomes.

Methods, level of evidence and grade of recommendation

To generate the recommendations summarized herein, a consensus group meeting was organized in Milan in November 2015 by ESMO and the Chordoma Foundation (CF). Representatives from the all the disciplines involved in care and treatment of patients with chordoma participated, including specialists in pathology, radiology, neurosurgery, ENT surgery, orthopedic surgery, general surgery, radiotherapy (RT), medical oncology, and palliative care (PC). A representative from main European, United States and Japanese RT centers with protons/carbon ions facilities and with experience in chordoma joined the meeting. Additional participants included patient representatives, statisticians, and molecular biologists. Prior to the meeting a literature search was conducted (details in the supplementary Appendix 1, available at Annals of Oncology online) to elucidate data upon which to base consensus recommendations. During the meeting, representatives from 14 of the participating institutions presented unpublished clinical data on patients treated with surgery and/or RT for recurrent chordoma from 2005. Based on these data and the literature review, the group reached consensus about key aspects of the management of patients with loco-regional recurrence, reported in this position paper. The present article is aimed at complementing the recommendations of the first position paper, published in 2015. To avoid repetition, this text contains several cross references to it [2].
We chose to grade level of evidence (LOE) from I to V and use grades of recommendation from A to D adapted from the system used by the Infectious Diseases Society of America-US Public Health Service Grading System 2 (Table 4). When published evidence was scarce but a strong consensus was present, we recorded the LOE as V. Points for which consensus among participating experts was not achieved are acknowledged herein. While stronger evidence would be desirable in many areas, we recognize the inherent difficulty of generating such data for rare cancers like chordoma, and, thus, accept that a higher degree of uncertainty must be tolerated for purposes of guideline development to avoid depriving rare cancer patients and those who care for them of much needed guidance [10].

**Treatment strategy**

Figure 1 summarizes the recommended treatment strategy for patients with loco-regional recurrence.

<table>
<thead>
<tr>
<th>Series (REF)</th>
<th>Year</th>
<th>N. of patients</th>
<th>Location</th>
<th>Resection rate (%)</th>
<th>Complications</th>
<th>Median follow-up (years)</th>
<th>1</th>
<th>2</th>
<th>5</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colli [45]</td>
<td>2001</td>
<td>19</td>
<td>Skull-base</td>
<td>T: 31</td>
<td>NA</td>
<td>3.2</td>
<td>74</td>
<td>NA</td>
<td>32</td>
<td>NA</td>
</tr>
<tr>
<td>Samii [47]</td>
<td>2007</td>
<td>23</td>
<td>Skull-base</td>
<td>GT: 52 ST: 48 NA</td>
<td>CSF: 0 (0, 12)c Post-haemorrhage: 0 (10)c Hydrocephalus: 9 (21)c Diffuse brain oedema: 0 (5)c Death for sepsis: 0 (5)c</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Sen [49]</td>
<td>2010</td>
<td>12</td>
<td>Craniovertebral junction</td>
<td>GT: 33</td>
<td>NA</td>
<td>5</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>–</td>
</tr>
<tr>
<td>Chibbaro [52]</td>
<td>2014</td>
<td>22</td>
<td>Skull-base</td>
<td>GT: 30 ST: 30 P: 40</td>
<td>NA</td>
<td>2.8</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>–</td>
</tr>
<tr>
<td>Gui [54]</td>
<td>2016</td>
<td>91</td>
<td>Skull-base</td>
<td>GT: 30 ST: 30 P: 40</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>–</td>
</tr>
</tbody>
</table>

Data on the outcome at a longer follow-up are frequently not available since primary and recurrent cases are not analysed separately.

*a* Total number of patients with evidence of recurrent chordoma, including those not operated at latest follow-up or dead for disease progression.

*b* Reported for reoperations (first and subsequent).

*c* In brackets, complication at second and third reoperation.

N of patients, number of patients with chordoma undergoing surgery after initial treatment; REF, reference; N, number; GT, gross total; ST, sub-total; D, death; NA, not available; CS, cavernous sinus.
### Table 2. Outcome of primary and locally recurrent mobile spine and sacrum chordoma patients treated with surgery plus or minus RT

<table>
<thead>
<tr>
<th>Series (REF)</th>
<th>Year</th>
<th>No. pts</th>
<th>Sacrum/mobile spine</th>
<th>Quality of margins</th>
<th>No. pts. receiving RT/surgery</th>
<th>Median FU (years)</th>
<th>OS rate primary (years)</th>
<th>OS rate recurrent (years)</th>
<th>LR rate primary (years)</th>
<th>LR rate recurrent (years)</th>
<th>Prognosticators for LR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Park [55]</td>
<td>2006</td>
<td>27</td>
<td>Sacrum=27</td>
<td>Mobile spine=0</td>
<td>R0=5</td>
<td>8.8 (mean)</td>
<td>93% at 10 years</td>
<td>44% at 10 years</td>
<td>9% at 10 years</td>
<td>81% at 10 years</td>
<td>R1/R2 margins Recurrent tumor</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sacrum/mobile spine</td>
<td>R1/R2=16</td>
<td>R0/R1=18</td>
<td></td>
<td></td>
<td></td>
<td>23% overall</td>
<td>53% overall</td>
<td>R1/R2 margins Recurrent tumor</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sacrum=0</td>
<td>R2=30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>R1/R2 margins Recurrent tumor</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Mobile spine=48</td>
<td>R0=48</td>
<td>R1=4</td>
<td>11.8</td>
<td>54% at 10 years</td>
<td>26% at 10 years</td>
<td>67% at 10 years</td>
<td>69% at 10 years</td>
<td>Large tumor size R1/R2 margins Recurrent tumor</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Mobile spine=22</td>
<td>R2=47</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No radiation therapy R1/R2 margins Recurrent tumor</td>
</tr>
<tr>
<td>Boriani [56]</td>
<td>2006</td>
<td>48</td>
<td>Sacrum=15</td>
<td>Mobile spine=29</td>
<td>R0=21</td>
<td>3.6</td>
<td>80% at 5 years</td>
<td>NR</td>
<td>38% at 5 years</td>
<td>NR</td>
<td>No pre-RT surgical stabilization</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sacrum/mobile spine</td>
<td>R2=19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Recurrent tumor</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sacrum=12</td>
<td>R0=7</td>
<td>R1=10</td>
<td>7.3</td>
<td>NR</td>
<td>NR</td>
<td>50% at 5 years</td>
<td>NR</td>
<td>R1/R2 margins Recurrent tumor</td>
</tr>
<tr>
<td>Staab [58]</td>
<td>2011</td>
<td>40</td>
<td>Sacrum=12</td>
<td>Mobile spine=29</td>
<td>R0=4</td>
<td>4.5</td>
<td>76% at 5 years</td>
<td>76% at 5 years</td>
<td>53% at 5 years</td>
<td>76% at 5 years</td>
<td>Large tumor size R1/R2 margins Recurrent tumor</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sacrum/mobile spine</td>
<td>R1=4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No radiation therapy R1/R2 margins Recurrent tumor</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sacrum=12</td>
<td>R2=16</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>R1/R2 margins Recurrent tumor</td>
</tr>
<tr>
<td>DeLaney [59]</td>
<td>2014</td>
<td>29</td>
<td>NR</td>
<td>NR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>R1/R2 margins Recurrent tumor</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sacrum=54</td>
<td>NR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No radiation therapy R1/R2 margins Recurrent tumor</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Mobile spine=0</td>
<td>NR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>R1/R2 margins Recurrent tumor</td>
</tr>
<tr>
<td>Xie [8]</td>
<td>2015</td>
<td>54</td>
<td>Sacrum=54</td>
<td>NR</td>
<td></td>
<td>7.8</td>
<td>82% at 5 years</td>
<td>56% at 5 years</td>
<td>51% at 5 years</td>
<td>NR</td>
<td>R1/R2 margins Recurrent tumor</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Mobile spine=0</td>
<td>NR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No radiation therapy R1/R2 margins Recurrent tumor</td>
</tr>
<tr>
<td>Rotondo [60]</td>
<td>2015</td>
<td>126†</td>
<td>Sacrum=71</td>
<td>Mobile spine=56</td>
<td>R0=34</td>
<td>3.4</td>
<td>81% at 5 years</td>
<td>78% at 5 years</td>
<td>32% at 5 years</td>
<td>51% at 5 years</td>
<td>Recurrent tumor Female patients</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sacrum/mobile spine</td>
<td>R1=57</td>
<td>R2=30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>R1/R2 margins Recurrent tumor</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sacrum=49</td>
<td>Mobile spine=7</td>
<td>R0=13</td>
<td>5.6</td>
<td>100% at 2 years</td>
<td>100% at 2 years</td>
<td>100% at 2 years</td>
<td>53% at 2 years</td>
<td>Recurrent tumor Female patients</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sacrum=188</td>
<td>Mobile spine=7</td>
<td>R0=13</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>R1/R2 margins Recurrent tumor</td>
</tr>
<tr>
<td>Uhl [61]</td>
<td>2015</td>
<td>56</td>
<td>Sacrum=49</td>
<td>Mobile spine=7</td>
<td>R0=13</td>
<td>2.1</td>
<td>100% at 2 years</td>
<td>100% at 2 years</td>
<td>100% at 2 years</td>
<td>53% at 2 years</td>
<td>Recurrent tumor Female patients</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sacrum=188</td>
<td>Mobile spine=7</td>
<td>R2=19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>R1/R2 margins Recurrent tumor</td>
</tr>
<tr>
<td>Imai [62]</td>
<td>2016</td>
<td>188</td>
<td>NR</td>
<td>NA</td>
<td>188(100%); 0(0%)</td>
<td>5.1</td>
<td>69% at 10 years</td>
<td>52% at 5 years</td>
<td>52% at 10 years</td>
<td>NR</td>
<td>R1/R2 margins</td>
</tr>
<tr>
<td>Radaelli [8]</td>
<td>2016</td>
<td>99</td>
<td>Sacrum=99</td>
<td>Mobile spine=0</td>
<td>R0=46</td>
<td>8.7</td>
<td>92% at 5 years</td>
<td>30% at 5 years</td>
<td>56% at 15 years</td>
<td>NR</td>
<td>Large tumor size R1/R2 margins Recurrent tumor</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sacrum/mobile spine</td>
<td>R1=43</td>
<td>R2=10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>R1/R2 margins Recurrent tumor</td>
</tr>
</tbody>
</table>

†One patient had synchronous lumbar and sacrococcygeal chordoma.

pts, patients; RT, radiotherapy; FU, follow-up; OS, overall survival; LR, local recurrence; NR, not reported; R0, wide resection; R1, marginal resection; R2, intralesional resection.
<table>
<thead>
<tr>
<th>Series (REF)</th>
<th>Year</th>
<th>N. pts</th>
<th>Type of RT</th>
<th>Dose and fractionation</th>
<th>Mean FU (years)</th>
<th>Oncological outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Series (REF)</strong></td>
<td><strong>Year</strong></td>
<td><strong>N. pts</strong></td>
<td><strong>Type of RT</strong></td>
<td><strong>Dose and fractionation</strong></td>
<td><strong>Mean FU (years)</strong></td>
<td><strong>Oncological outcome</strong></td>
</tr>
<tr>
<td><strong>Skull base</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Munzenrider [63]</td>
<td>1999</td>
<td>290</td>
<td>Surgery + protontherapy (passive fields) + photon RT</td>
<td>Protons 4 fx/week (1.92 CGE) Photons 1 fx/week (1.8 Gy)</td>
<td>3.4</td>
<td>5-year LRFS 73% chordoma</td>
</tr>
<tr>
<td>Noel [64]</td>
<td>2005</td>
<td>88</td>
<td>Surgery + protontherapy (passive fields)</td>
<td>Median dose 67 CGE with standard fractionation</td>
<td>2.6</td>
<td>2-year LC 86%</td>
</tr>
<tr>
<td>Ares [65]</td>
<td>2009</td>
<td>41</td>
<td>Surgery + protontherapy (active spot scanning)</td>
<td>Median total dose 73.5 Gy (RBE) with standard fractionation</td>
<td>3.2</td>
<td>5-year LC—81%</td>
</tr>
<tr>
<td>Mizoe [66]</td>
<td>2009</td>
<td>33</td>
<td>Surgery + carbon ions (passive fields)</td>
<td>Dose escalation 48.0, 52.8, 57.6, and 60.8 Gy in 16 fractions</td>
<td>4.4</td>
<td>5-year LC—85% 10-year LC—64%</td>
</tr>
<tr>
<td>Uhl [61]</td>
<td>2014</td>
<td>155</td>
<td>Surgery + carbon ions (active spot scanning)</td>
<td>60 Gy RBE 3 Gy RBE per fraction</td>
<td>6</td>
<td>5-year LC—72% 10-year LC—54% Overall LC 48%6-year PFS 35.2%</td>
</tr>
<tr>
<td>Choy [67]</td>
<td>2016</td>
<td>57</td>
<td>Surgery + stereotactic radiotherapy (SRS) or stereotactic radiotherapy (SRT)</td>
<td>SRS 17.8 Gy SRT 63.4 Gy Hypofractionated schedule</td>
<td>4.8</td>
<td></td>
</tr>
<tr>
<td>Bugoci [68]</td>
<td>2013</td>
<td>12</td>
<td>Surgery + fractionated stereotactic radiotherapy</td>
<td>Median dose 66.6 Gy with standard fractionation</td>
<td>3.5</td>
<td>5-year PFS 37.5%</td>
</tr>
<tr>
<td>Kano [69]</td>
<td>2011</td>
<td>71</td>
<td>Surgery + Gamma Knife stereotactic radiosurgery (SRS)</td>
<td>Median margin dose 15.0 Gy (range 9–25 Gy)</td>
<td>5</td>
<td>5-year LC 66%</td>
</tr>
<tr>
<td>Chang [70]</td>
<td>2001</td>
<td>10 (8 skull base, 2 cervical spine)</td>
<td>Surgery + LINAC stereotactic radiosurgery</td>
<td>Mean radiation dose 19.4 Gy</td>
<td>4</td>
<td>Gross LC 80%</td>
</tr>
<tr>
<td>Zorlu [71]</td>
<td>2000</td>
<td>18</td>
<td>Surgery + 3D photons RT</td>
<td>Median 60 Gy with standard fractionation</td>
<td>3.6</td>
<td>5-year PFS 23%</td>
</tr>
<tr>
<td>Foweraker [72]</td>
<td>2007</td>
<td>12 (10 clivus, 2 cervical spine)</td>
<td>Surgery + photons radiotherapy</td>
<td>65 Gy in 39 fractions</td>
<td>3.2</td>
<td>Gross LC 92%</td>
</tr>
<tr>
<td><strong>Sacrum and spine</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imai [62]</td>
<td>2016</td>
<td>188</td>
<td>Exclusive carbon ions (passive fields)</td>
<td>Median 67.2 GyE in 16 fractions</td>
<td>5.2 (median)</td>
<td>Primary tumor 10-year OS 69% 5-year LC 77.2% Recurrent tumor 10-year OS 52%</td>
</tr>
<tr>
<td>Uhl [61]</td>
<td>2015</td>
<td>56 (41 primary tumors, 15 recurrent tumors)</td>
<td>Carbon ions (active scanning) or photons RT and carbon ions (active scanning) + surgery (10 R0/R1 resection 11 R2 resections 20 biopsy only, 15 recurrences)</td>
<td>Median 66 GyE</td>
<td>2.1</td>
<td>Primary tumor 2-year OS 100% 2-year LC 100% Recurrent tumor 2-year OS 100% 2-year LC 47%</td>
</tr>
<tr>
<td>Mima [73]</td>
<td>2014</td>
<td>23</td>
<td>Exclusive carbon ions or exclusive protontherapy</td>
<td>70.4 GyE in 16 fractions in 32 fractions</td>
<td>3.2</td>
<td>3-year LC—94%</td>
</tr>
<tr>
<td>Rotondo [60]</td>
<td>2015</td>
<td>126 (71 sacrococcygeal, 40 lumbar, 16 thoracic)</td>
<td>Surgery + protontherapy</td>
<td>Median 72.4 Gy RBE with standard fractionation</td>
<td>3.5</td>
<td>Primary tumor 5-year OS 81% 5-year LC 68% Recurrent tumor 5-year OS 78% 5-year LC 49%</td>
</tr>
</tbody>
</table>
### Table 3. Continued

<table>
<thead>
<tr>
<th>Series (REF)</th>
<th>Year</th>
<th>N. pts</th>
<th>Type of RT</th>
<th>Dose and fractionation</th>
<th>Mean FU (years)</th>
<th>Oncological outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Holliday [74]</td>
<td>2015</td>
<td>19</td>
<td>Surgery+protontherapy</td>
<td>Median 70 Gy RBE with standard fractionation</td>
<td>32.9</td>
<td>2-year LC—58%</td>
</tr>
<tr>
<td>DeLaney [59]</td>
<td>2014</td>
<td>29 (23 primary, 6 recurrent)</td>
<td>Surgery+protontherapy</td>
<td>77.4 Gy RBE with standard fractionation</td>
<td>7.3</td>
<td>Primary tumor 5-year LC 100% 8-year LC 92% Recurrent tumor 5-year LC 50% 5-year LPFS 79.8%</td>
</tr>
<tr>
<td>Chen [75]</td>
<td>2013</td>
<td>24 (19 sacrum, 2 cervical, 1 thoracic, and 2 lumbar spine)</td>
<td>Exclusive protontherapy (passive fields)</td>
<td>77.4 Gy RBE (range 71.6–79.2 Gy RBE) with standard fractionation</td>
<td>4.7</td>
<td></td>
</tr>
<tr>
<td>Staab [58]</td>
<td>2011</td>
<td>40 (32 primary, 8 recurrent) (21 adjuvant RT, 19 macroscopic disease)</td>
<td>Protontherapy spot scanning+radical surgery</td>
<td>72.5 Gy RBE with standard fractionation</td>
<td>3.6</td>
<td>5-year OS 80% 5-year LC 62%</td>
</tr>
<tr>
<td>Dhawale [76]</td>
<td>2014</td>
<td>21 (sacrum)</td>
<td>Surgery+(18)—(3) 3D conformal RT or IMRT</td>
<td>Mean dose 56 Gy with conventional fractionation</td>
<td>5.8</td>
<td>Gross LC 60%</td>
</tr>
<tr>
<td>Zabel-du Bois [57]</td>
<td>2010</td>
<td>34</td>
<td>First diagnosis: surgery+adjuvant IMRT (13) or IMRT alone (4) Recurrent tumor Surgery+adjuvant IMRT (11) or IMRT alone (6)</td>
<td>Mean dose 66 Gy with conventional fractionation</td>
<td>4.5</td>
<td>Primary tumor 5-year OS 76% 5-year LC 47% Recurrent tumor 5-year OS 76% 5-year LC 24%</td>
</tr>
</tbody>
</table>

There is no paper specifically reporting the outcome of relapsed chordoma treated with RT. Most series include both first line RT and salvage treatments.

N, number; pts, patients; RT, radiotherapy; FU, follow-up; CGE, cobalt gray equivalent; LRFS, local recurrence-free survival; LC, local control; RBE, relative biological effectiveness; Gy, Gray; PFS, progression-free survival; GyE, Gray equivalent; OS, overall survival; IMRT, intensity-modulated radiation therapy; LINAC, linear accelerator; R0, wide resection; R1, marginal resection; R2, intraslisional resection.

### Table 4. Level of evidence and grade of recommendation

Adapted from the Infectious Diseases Society of American-United States Public Health Service Grading System.

**Level of evidence**
- I. Evidence from at least one large randomized controlled trial of good methodological quality (low potential for bias) or meta-analyses of well conducted randomized trials without heterogeneity
- II. Small randomized trials or large randomized trials with a suspicion of bias (lower methodological quality) or meta-analyses of such trials or of trials with demonstrated heterogeneity
- III. Prospective cohort studies
- IV. Retrospective cohort studies or case-control studies
- V. Studies without control group, case reports, and experts’ opinions

**Grade of recommendation**
- A. Strong evidence for efficacy with a substantial clinical benefit, strongly recommended
- B. Strong or moderate evidence for efficacy but with a limited clinical benefit, generally recommended
- C. Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages (including adverse events and costs), optional
- D. Moderate evidence against efficacy or for adverse outcome, generally not recommended
- E. Strong evidence against efficacy or for adverse outcome, never recommended

To distinguish prospectively planned studies from retrospective case series, we assigned the level of evidence V followed by “*” to single-group prospective trials.

The guidelines were adapted from the Infectious Diseases Society of America-US Public Health Service Grading System.
Patients who experience LR should be evaluated by a multidisciplinary team including at least a medical oncologist, radiotherapist, surgeon, pathologist, radiologist and PC specialist with expertise in chordoma. This recommendation is consistent with best practice for managing musculoskeletal neoplasms [11].

The presence/absence of symptoms should be factored in the decision-making algorithm. It is important to involve the patient when deciding which treatment to pursue.

The ‘extent of local disease’ should be determined using intravenous contrast-enhanced MRI. In addition, restaging with total body computed tomography scan (CT) and whole spine MRI with a thorough clinical examination should complement local-regional assessment to rule out distant metastases and/or subarachnoid spread.

‘Histological confirmation’ of recurrent disease is needed when there is diagnostic uncertainty, or when there is the suspicion of tumor dedifferentiation (e.g. unusually fast growth), or of a secondary malignancy. In cases where a tumor relapse is uncertain, a period of observation and re-imaging is an appropriate alternative to histologic assessment. A biopsy can be considered in selected cases for directing medical therapy.

‘Salvage’ treatment choices with curative intent can include surgery and/or RT, balancing morbidity, QOL and expected disease control. Surgical and RT strategy should be guided by the nature and extent of the previous procedure(s), the location of the recurrence, tumor resectability, deliverability of RT and the expected added morbidity of each procedure. Other relevant factors to consider include age, comorbidity, performance status (PS), and status of the surrounding tissues including the skin. The choice between surgery alone, surgery + RT, and RT alone must be based on individual case assessment; to date, there are no specific data to back generalized recommendations. A period of observation and re-imaging may help select best candidates for resection/RT or both.

In particular, postponing active therapy can be considered in case of stable disease and/or no progression of symptoms.

The goal of ‘salvage’ re-resection with curative intent should be to achieve gross total resection, and, when feasible, en-bloc resection with negative surgical margins (IV-B). The best candidates for a complete re-resection are patients with isolated disease, a long disease-free interval, good PS (i.e. Eastern Cooperative Oncology Group-ECOG PS ≤ 2) and with a reasonable likelihood of acceptable morbidity. In cases of multifocal disease, a cure is virtually impossible so re-resection with curative intent should not be performed (IV-B); in these cases, only a limited resection should be considered with the goal of preventing the ill effects associated with disease progression whilst preserving function. A prior history of piecemeal resection (except for skull-base tumors where resection may be necessarily piecemeal), prior high-dose RT (in case of mobile spine and sacral chordoma), and/or tumor rupture are obvious exclusion criteria for re-resection with curative intent (IV-B). There is no consensus on how to treat intracanalar disease. In patients who have not previously received high-dose RT at the time of primary treatment, pre- and/or post-operative treatment with RT may also be appropriate [12, 13]. This approach is currently the standard treatment strategy in primary disease at some referral centers [14] and may be particularly well suited for treating local recurrences as the chance of achieving a true R0 resection after prior surgical procedures is low. It is currently not possible to make any recommendations regarding the role of adjuvant re-irradiation after macroscopically complete resection of recurrent chordoma.

‘Salvage’ radiotherapy with curative intent should be offered with the same dose and techniques as employed in first-line therapy [2]. Thus, in case of recurrence in patients not previously treated with RT, definitive RT alone (e.g. without debulking) is a
reasonable alternative to surgery plus radiation, although neither is very effective (V-C). Comparative effectiveness data for these approaches are limited and additional research is needed to determine which approach is superior. Patients considering definitive RT need to be informed about the risk of late toxicities from high-dose radiation (IV-B).

In the case of recurrent disease after previous RT, a new course of RT is indicated only when (i) this can be delivered without exceeding the estimated dose constraints on organs at risk (OARs) and (ii) adequate coverage of target volumes can be achieved. If this is not feasible, other treatment modalities are preferable (V-C). Currently, the cumulative dose tolerance for key OARs and the potentially protective role of partial damage repair after the first course of RT are still largely unknown. When complete resection of a recurrent lesion is not feasible, and proximity to critical structures precludes adequate RT coverage of target volumes, debulking surgery may be an appropriate option in order to separate critical structures from the residual tumor, thereby allowing delivery of a tolerable radiation dose.

‘Salvage palliative/supportive treatment choices’ include debulking surgery, low-dose RT, stereotactic body RT (SBRT), including radiosurgery to small volume, radiofrequency ablation (RFA) and other loco-regional approaches (i.e. cryotherapy), systemic therapy, PC and observation. The patient’s symptom burden should guide the selection of an appropriate therapeutic approach as the potential for cure is nil. Care should be taken to avoid aggressive therapies that could cause unnecessary additional morbidity. Maximal debulking surgery should only be considered to alleviate or prevent symptoms related to nerve/cord/brain compression or for separating vital structures from the tumor to allow for radiation of the residual disease (V-C). This type of surgery is indeed only a temporizing measure, as local disease that remains after surgery will regrow in the region. Particular caution should be exercised in performing surgery near prior high-dose RT (IV-C) as the risk of surgical complications is dramatically greater in this setting. Additionally, the oncologic outcome generally deteriorates, and the chance of mortality and serious morbidity increases, with each serial resection (IV-B). Low-dose re-irradiation with palliative intent can be considered in selected case if it can be performed with negligible risk of toxicity (V-C).

‘PC’ should be considered as part of the active management of all patients and should include pain and symptom control, discussion about a patient’s concerns and wishes, a conversation about advanced directives, and evaluation of patient and family psychosocial needs.

‘Salvage palliative anticancer medical therapy’ should be considered to attempt to stop tumor growth and/or alleviate symptoms in cases not amenable to local treatment or when symptomatic relief is needed, taking into consideration the PS, co-morbidities, expected treatment-related side effects, and the patient’s preferences (V*-B).

### Technical aspects of treatment

#### Pre-treatment assessment

**Imaging.** Any relevant imaging studies performed prior to and after treatment of the primary chordoma should be obtained and reviewed. The first post-operative baseline imaging should be evaluated to confirm the initial extent of resection. Likewise, the post-radiation imaging at best response should be evaluated to assess the extent of residual disease. A comparative analysis of the imaging from first diagnosis to recurrence is important to distinguish recurrent disease from treatment sequelae and for assessing areas at high-risk of microscopic infiltration.

Although MRI is the modality of choice, CT may be a useful ancillary imaging modality, particularly to assess the bone involvement and when surgical implants or hardware limit MRI reliability. Myelo-CT can be useful to visualize peridural spaces when chordoma tissue invades the spinal canal. Furthermore, CT is a helpful tool in assessing stability of the spinal column.

For patients with skull-base tumors, assessment of internal carotid artery (ICA) and/or vertebral arteries with angi-CT can be needed for surgical planning. If curative surgery is considered, formal angiography with balloon test occlusion can be considered if ICA involvement is a limiting factor for tumor resection.

FDG-PET may be used in combination with other modalities in certain cases to exclude distant relapse and/or to evaluate tumor activity when tumor dedifferentiation is suspected or if a lesion is not clearly recurrent tumor.

**Pathology.** At the time of recurrence, the primary excised chordoma sample, including immunohistochemistry for brachyury and cytokeratin, should be reviewed and confirmed by an expert pathologist. The diagnosis should be based on the World Health Organization (WHO) Classification [1].

Tumor biopsy of recurrent disease, when warranted, must be performed with every attempt to limit the risk of tumor seeding [2]. A percutaneous core-needle biopsy is the preferable approach.

If a biopsy is obtained, it should be compared with the primary tumor to assess whether the tumor has changed or dedifferentiated over time. Dedifferentiated chordoma can show a deletion of INI1, which is a potentially targetable molecular alteration [15, 16].

**Baseline patient evaluation.** Prior to treatment, a complete physical examination and neurological assessment should be performed. For skull-base chordomas, endocrinological, ophthalmological and audiological examination is suggested. The patient’s symptoms and pace of symptom progression should be noted. Pain assessment should be performed using a 0–10 pain assessment scale [17]. Chronic pain secondary to RT or surgery should be distinguished from acute symptoms related to tumor progression for purposes of considering treatment approaches.

The evaluation should also include a detailed review of notes describing prior resections and/or RT, including but not limited to fields, dose and type of RT. The location of previous incisions or biopsies should be noted in relationship to new tumor lesion(s) for purposes of surgical planning.

**Resection of recurrent or progressive disease**

For mobile spine and sacral tumors, the goal of salvage surgery with curative intent should be to achieve en-bloc resection with negative surgical margins (IV-B). Particular attention should be paid to avoid tumor rupture, as this is associated with significant risk of tumor seeding. Recurrences in the skull-base or neck, as
Radiotherapy of recurrence

RT can be delivered both with curative or palliative intent. To achieve local control in recurrent chordoma it is necessary to give a biologically high-dose while limiting the cumulative dose delivered to the critical structures near the target volume (IV-B). The feasibility and utility of RT for patients with recurrent chordoma depends primarily on whether or not the patient received RT to the same area as part of primary management. Thus, recommendations are presented below for two scenarios: patients without and with previous irradiation.

RT in patients without previous irradiation. Salvage RT with curative intent should be offered with the same modality employed for first line therapy (V-C) [2]. Since chordomas are radioresistant, a dose of at least 74 GyE should be delivered, using conventional fractionation (1.8–2 GyE) for photon and proton therapy (V*-A); moderately hypofractionated schedules can be used with carbon ions with dose per fractions ranging between 3 and 4.4 Gy RBE and total doses ranging from 60 and 70.4 Gy RBE [2]. Prior to RT, surgical re-resection should be discussed in all cases. Target volumes should be delineated considering the primary tumor location and its recurrence. The high-dose volume should include any macroscopic disease as well as surgical margins, while the low-dose volume should encompass areas at risk of microscopic spread, skip metastases, or seeding due to surgical procedures. In selected cases, a radio-surgical approach to gross disease may be appropriate, although there is no consensus as of yet about the criteria for recommending it.

RT in patients with previous irradiation. The radiation dose previously received by nearby OARs often limits the dose of radiation that can be safely delivered to the tumor, making local control of recurrences challenging. In general, the dose constraints for re-irradiation to OARs are not clearly established and the degree of recovery from initial radiation is difficult to estimate. However, preliminary data are available regarding tolerance to re-irradiation of the spinal cord, brain and aorta, which can help guide decision-making [7, 19–22]. If a new course of high-dose RT can be delivered without exceeding the estimated dose constraints on OARs, the patient should be treated with the same intent and approach as a RT naïve recurrence (V-C). Radiation plans must be based on an accurate reconstruction of the previous RT dose distribution, and taking into account expected morbidity of additional radiation (V-C). In case of tumor seeding in the surgical pathway, the site of relapse is often outside the previously irradiated volume and can be adequately treated by radiation [7]. The radiotherapist must exercise professional judgment in developing the radiation plan, as there is currently insufficient data to recommend an optimal dose and fractionation scheme for radiation in this setting. Regardless, particular caution is warranted in re-irradiating the carotid artery as severe, life-threatening complications such as carotid blowout syndrome have been reported in patients treated with re-irradiation for head and neck cancer [23]. If re-irradiation cannot achieve sufficiently high-dose or adequate coverage of target volumes without exceeding estimated dose constraints, then other treatment modalities are preferable. Low-dose re-irradiation with palliative intent can be appropriate in selected cases but only if it can be performed with negligible risk of toxicity. The use of high LET (Linear Energy Transfer) radiation such as carbon ions can be considered especially in case of re-irradiation after an initial course of low LET treatment as it may be more effective against the radio-resistant clones that may have been selected by the first treatment. Metal implants (e.g. for spine stabilization) complicate RT delivery by creating artifacts in CT/MRI images. This can interfere with precise delineation of target and OAR, especially in the spinal canal. Additionally, these artifacts affect range calculation for particle therapy, and, therefore, may result in an additional uncertainty in delivered dose. Consequently, the presence of metal implants may be a key factor in deciding not to deliver curative RT or in deciding to deliver it with photons, which are less sensitive to artifacts, instead of particles (IV-B). If a debulking or a separating surgery is planned, the possibility of modifying, removing or substituting metal implants with carbon fiber devices should be considered to enable radiation with potentially curative intent; however, this is appropriate only in very well selected cases after thorough multidisciplinary assessment.

Other local therapies

Retrospective data suggest that cryoablation and RFA can be safe and useful palliative treatments in recurrent extracranial chordomas with a benefit in pain control [24–26]. However, prospective studies are needed before recommending these procedures in chordoma.

SBRT, including radiosurgery, has been described in retrospective and prospective series as safe and effective salvage strategy for spine tumors that have recurred after prior RT [27]. SBRT has been suggested as a palliative treatment option also in chordoma patients who suffer LR after prior RT [28], nevertheless prospective confirmatory data are necessary to make any definitive recommendations.

In principle, other local therapies such as local microwave hyperthermia and high-intensity focused ultrasound (HIFU) may also offer benefit in a palliative setting; however, currently there are no published data supporting their use.

Medical therapy

Medical therapy is an appropriate palliative option for patients whose disease is actively progressing or who are symptomatic. A brief observation period may be warranted before starting medical therapy to determine whether, and at what rate, the disease is
progressing. If no progression is detected, it may be more appropriate to continue with active surveillance. Currently, medical therapy options are limited and no drugs are approved for the treatment of advanced chordoma. However, several targeted therapies have shown modest activity in patients with recurrent disease. Imatinib and sorafenib are the agents with the greatest evidence of efficacy in advanced chordoma and represent reasonable palliative treatment options to slow disease progression or alleviate symptoms [29–32]. Access to these drugs varies widely among countries, posing a challenge for patients in some areas. In addition, several case reports have noted activity of sunitinib and EGFR inhibitors (cetuximab, erlotinib, gefitinib) [33–38].

Cytotoxic chemotherapy is generally inactive, and there is insufficient evidence to recommend it [V-D]. However, there are anecdotal reports of responses to chemotherapy in high-grade/dedifferentiated chordoma and in some pediatric cases [39].

Although no predictors of response to targeted agents have been identified in chordoma, molecular profiling of tumors may help guide selection of experimental therapies. One potentially relevant biomarker is INI1 loss, which has been reported in dedifferentiated chordomas and may confer sensitivity to EZH2 inhibitors [15, 16].

A more detailed and up to date description of published data on medical therapy in chordoma is provided in supplementary Appendix 2, available at *Annals of Oncology* online.

### Palliative, supportive and end-of-life care

PC is part of the active care of patients with advanced illness [40]. A comprehensive PC approach and access to specialized PC are both necessary (Table 5) [41].

Most chordoma patients suffer from both somatic and neuropathic pain that can be difficult to treat. Worsening of pain and/or of neurologic symptoms can be the first sign of disease relapse/progression even when this cannot be yet detected radiologically [42].

First-line analgesic therapy should be provided by the oncology team according to available guidelines [43]. Pain due to the compression of nervous tissues via epidural compression or radiculopathy often benefits from steroids (dexamethasone or methylprednisolone). Difficult pain syndromes poorly responsive to analgesic pharmacotherapy can benefit from more invasive analgesic techniques such as spinal administration of opioids, ziconotide and adjuvant drugs [44].

In the terminal phase, the patient’s preferred setting of care should be identified. Hospice and home-care are valid options depending on the patient’s and family’s preferences.

### Follow-up

Currently, there is insufficient data to recommend an optimal routine follow-up policy for patients with recurrent chordoma. Thus, follow-up is usually chosen based on the best judgment of the patient’s care team. However, experts agreed that MRI should be performed every 3–6 months at least for the first 3 years from treatment of LR/local progression. There is currently no consensus about whether routine scanning of the rest of the body is beneficial and for how long follow-up should be continued, though long-term vigilance is warranted as relapses often take place after several years.

### Emerging approaches and future directions

For those patients who fail surgery and RT, there remains an urgent unmet need for new therapeutic options. To facilitate
patient participation in clinical trials, the CF maintains an up to date list of trials open to chordoma patients (www.chordomafoundation.org/clinical-trials/) and a ‘target dashboard’ (www.chordomafoundation.org/targets/) summarizing published data about therapeutically-relevant targets.

Future clinical trials should be designed considering the rarity and distinctive natural history of chordoma. Due to its rarity, performing randomized trials may not be feasible. Additionally, due to its characteristically slow growth-rate and relatively long expected OS period, determining an OS benefit is likely impractical, thus necessitating the use of surrogate endpoints to assess efficacy. However, because patients often experience prolonged periods of asymptomatic disease progression prior to end-stage disease, conventional surrogate endpoints based solely on dimensional response may miss improvements in QOL, and, thus, may be inadequate for inferring clinical benefit. New, and possibly unconventional, approaches are needed for assessing efficacy and facilitate the pathway to drug approval. Meanwhile, patients should be enrolled in prospective registries or observational studies to better understand the natural history of chordoma and identify relevant correlates of outcome that could aid in future trial design and help optimize clinical care.

Acknowledgements

We are deeply indebted with the Chordoma Foundation and with F. Longo, from the European Society for Medical Oncology (ESMO), for their invaluable support to the consensus building process, without which this effort would not have been possible. We are also deeply grateful to Chordoma Foundation European Liaison Hans Keulen, who, sadly, lost his battle with chordoma prior to completion of this article, for inspiring and helping to spearhead this international consensus-building effort.

Funding

None declared.

Disclosure

The authors have declared no conflicts of interest.

Outside this work: SS: grants and personal fees from Novartis and Epizyme; grants from Bayer, GlaxoSmithKline, Pfizer; AG: personal fees from Bayer, Glaxo, Novartis and Pfizer; NH: nonfinancial support from Bayer; JMB: personal fees from Bayer, Glaxo and Novartis; CM: grants from Epizyme and Novartis; SP: personal fee from Bayer, Merk Serono; PR: grants and personal fees form Novartis, personal fees for Brystol-Meyers Squibb, personal fees from Merck Serono and Pfizer; SS: personal fees and grant from Chordoma Foundation, nonfinancial support from Glaxo; PGC: grants and personal fees from Bayer, Glaxo, Novartis and Pfizer; personal fees from Merk Serono, grants from Epizyme; JS reported grant from Bristol-Myers Squibb; TA, CA, MB, JYB, SB, RC, AC, RC, VC, JD, TD, AD, PD, SD, FD, AF, PF, SF, PAG, HG, ZLG, RH, CH, PH, FH, RI, LJ, RLJ, BK, AK, MK, AL, IL, DM, PN, OJN, NP, PP, SP, SR, FR, CS, ET, KAT, BT, VT, PUT, MU, YY, DCW, DV, PPV, CLAV-L declared no competing interests.

References

4. Tzortzidis F, Elahi F, Wright D et al. Patient outcome at long-term follow-up after aggressive microsurgical resection of cranial base chordo-

7. McDonald MW, Linton OR, Moore MG et al. Influence of residual tumor volume and radiation dose coverage in outcomes for clival chor-
10. Casali PG, Bruzzi P, Bogaerts J et al. Rare Cancers Europe (RCE) meth-

11. Randall RL, Bruckner JD, Papenhausen MD et al. Errors in diagnosis and margin determination of soft-tissue sarcomas initially treated at non-


73. Mima M, Demizu Y, Jin D et al. Particle therapy using carbon ions or protons as a definitive therapy for patients with primary sacral chondroma. Br J Radiol 2014; 87(1033):

